MedTrace Logo

Cord Blood Microtransplantation for Treatment of Acute Myeloid Leukemia

NCT04174586 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-03-26

No results posted yet for this study

Summary

Discuss the effectiveness and safety of cord blood microtransplantation for treatment of acute myeloid leukemia

Conditions

  • Safety Issues
  • Efficiency

Interventions

BIOLOGICAL

microtransplantation

HLA mismatched donor cord blood infusion

Sponsors & Collaborators

  • The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

    lead OTHER

Principal Investigators

  • Zimin Sun · The First Affiliated Hospital of USTC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-22
Primary Completion
2024-08-31
Completion
2024-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04174586 on ClinicalTrials.gov